MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financi... (er assets ...)

MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results

Date:2/28/2008

er assets 122 384

Total assets $100,695 $21,625

Liabilities, redeemable convertible preferred

stock and stockholders' equity (deficit)

Current liabilities:

Accounts payable and accrued expenses $8,912 $4,091

Current portion of long-term debt 3,820 840

Total current liabilities 12,732 4,931

Long-term debt, less current portion 6,357 10,061

Redeemable convertible preferred stock

warrant liability -- 411

Total liabilities 19,089 15,403

Redeemable convertible preferred stock -- 64,898

Total stockholders' equity (deficit) 81,606 (58,676)

Total liabilities, redeemable convertible

preferred stock and stockholders' equity

(deficit) $100,695 $21,625

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Operating expenses:

Research and development $13,019 $7,171 $31,362 $22,268

Sales, general and

administrative 2,744 1,261 9,567 4,128

Total operating expenses 15,763 8,432 40,929 26,396

Loss from op
'/>"/>

Post Your Comments:

MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financi...(er assets ...),Health